Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
03/2005
03/31/2005WO2005028426A1 Novel 4-phenylamino-benzaldoxime derivative and use thereof as mek inhibitor
03/31/2005WO2005027973A2 Combinations of a vegf receptor inhibitor with other therapeutic agents
03/31/2005WO2005027969A1 Remedy for eye diseases accompanied by optic nerve injuries
03/31/2005WO2005027951A1 Method for controlling angiogenesis in animals
03/31/2005WO2005027947A1 Oral compositions for the treatment of cellulite
03/31/2005WO2005027896A1 Concurrent drugs
03/31/2005WO2005027895A2 Thyroid hormone analogs and methods of use in angiogenesis
03/31/2005WO2005027892A1 Early insulin secretion promoter
03/31/2005WO2005027891A1 Accelerator for initial insulin secretion
03/31/2005WO2005027886A2 Methods of preventing or treating recurrence of myocardial infarction
03/31/2005WO2004105679A3 Use of a nutritional composition for treating hypertension
03/31/2005WO2004075856A3 Adenosine a1 receptor antagonist for the treatment of cardiac and renal diseases
03/31/2005WO2004010951A8 Method of treating tumors
03/31/2005WO2003099215A3 Antisense modulation of glucocorticoid receptor expression
03/31/2005WO2003073987A3 Compounds that modulate the activity of ptp-1b and tc-ptp
03/31/2005WO2003040329A3 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
03/31/2005WO2003018756A3 Methods for preparing purified prostaglandin e synthase
03/31/2005WO2002042319A9 2-substituted estrogens as antiangiogenic agents
03/31/2005US20050070720 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
03/31/2005US20050070719 Central nervous system disorders; antidiabetic agents; antiinflammatory agents; antiarthritic agents;obesity; osteoporosis ; anticancer agents
03/31/2005US20050070713 Neurokinin antagonist; therapy for central nervous system disorders; psychological disorders; Parkinson's and Huntington's disease
03/31/2005US20050070689 Nucleotide sequences coding transmembrane activator and CAML interactor (TACI) protein for use in treatment and prevention of autoimmune disorders
03/31/2005US20050070605 Reacting an organophosphouus compound with metallized alkane; forming atorvastatin, lorastatin, pitavastatin, fluvastatin
03/31/2005US20050070594 Use of angiotensin II receptor antagonists
03/31/2005US20050070590 possessing anti-cancer activity, anti-inflammatory activity, anti-obesity activity, and/or hair growth promotion activity
03/31/2005US20050070582 For example,1-{[2-(3,5-dimethylphenoxy)-5-nitrophenyl]sulfonyl}-4-ethylpiperazine or 1-{[2-(3,5-dichlorophenoxy)-5-nitrophenyl]sulfonyl}piperazine; for the treatment of asthma, atopic dermatitis, allergic rhinitis and other inflammatory/immunological disorders
03/31/2005US20050070581 such as 3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-4-methoxybenzylidene-2,4-thiazolidinedione; Hodgkin's disease
03/31/2005US20050070574 Novel compounds
03/31/2005US20050070569 Alkyne-aryl phosphodiesterase-4 inhibitors
03/31/2005US20050070566 Imidazoquinoline derivatives
03/31/2005US20050070559 Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
03/31/2005US20050070558 For example, [4-(2,4-Dioxo-1,3-dipropyl-2,3,4,5-tetrahydro-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetic acid; useful in preventing mast cell degranulation and therefore useful in treatment of diseases induced by activation of A2b receptor and mast cell activation such as asthma, allergic reactions
03/31/2005US20050070557 Use of pyrazolo(4,3-d)pyrimidine derivatives; for example, 5-(3-chloro-benzyl)-3-isopropyl-1,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one
03/31/2005US20050070555 Aroyl pyridinones
03/31/2005US20050070553 Pharmaceutical composition comprising an alpha-glucosidase inhibitor and a 4-oxobutanoic acid, and the use thereof for treating diabetes
03/31/2005US20050070552 Ion channel modulating activity I
03/31/2005US20050070546 Tyrosine kinase inhibitors
03/31/2005US20050070541 Enzyme inhibitors of cGMP-metabolizing phosphodiesterases, for TREATMENT OF CARDIOVASCULAR DIORDERS, CEREBROVASCULAR DISORDERS, UROGENITAL DISORDERS AND ERECTILE DYSFUNCTION; chemical synthesis
03/31/2005US20050070529 Use of type 4 phosphodiesterase inhibitors in myocardial diseases
03/31/2005US20050070525 Such as 3-[2-[4-(11,12-dihydro-6H-benzimidazo[2,1-b][3]benzazepin-6-yl)-2-(phenyl-methyl)-1-piperidinyl]ethyl]-2,10-dimethyl pyrimido[1,2- alpha ]benzimidazol-4(10H)-one
03/31/2005US20050070517 Oxazol/thiazol-derivatives activators of the hppar-alpha receptor
03/31/2005US20050070505 Phosphinic pseudo-peptide derivatives for the selective inhibition of the active c-terminal site of angiotensin converting enzyme (I) (ace)
03/31/2005US20050070485 Phenylalanine derivatives
03/31/2005US20050070484 Treating retinopathy both of diabetes and prematurity, or tumor growth
03/31/2005US20050070481 By adding an antioxidant and/or a chelating agent in the same aqueous solution; reduced coenzyme Q10, vitamin C and ethylenediaminetetracetic acid for example
03/31/2005US20050070470 Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
03/31/2005US20050070466 Diagnostic imaging agents; targeting vectors which bind to integrin receptors; bicyclic arginine-glycine-aspartic acid derivatives; stablility; reduced background interference
03/31/2005US20050069878 Proteins associated with cell growth, differentiation, and death
03/31/2005US20050069877 Protein modification and maintenance polypeptides (PMOD) for use as diagnostic and therapeutic tools in treatment of prevention of gastrointestinal, cardiovascular, autoimmune/inflammatory, cell proliferative, developmental, epithelial, neurological, and reproductive disorders
03/31/2005US20050069876 Polypeptide for use in diagnosis, treatment and prevention of cell proliferative, autoimmune, inflammatory, cardiovascular, neurological and developmental disorders.
03/31/2005US20050069598 Antidiabetic agents; moderate glucagon-like peptide; phosphoenolpyruvate carboxykinase inhbitors; weight control
03/31/2005US20050069577 Synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies
03/31/2005US20050069557 A protein neuroglobin derived from neuronal tissue; binging, storage oxygen; therapy for central nervous system disorders
03/31/2005US20050069547 Binding protein; therapy for bone tumors
03/31/2005US20050069537 Stimulants of survival of cells; binding of cellular adhesion molecular; prevent apoptosis
03/31/2005US20050069533 Process of preparation of formulations of the peptide angiotensin-(1-7) and its analogues, agonistic and antagonists using cyclodextrins, lipossomes and biodegradable polymers and/or mixtures and products thereof
03/31/2005US20050069492 As neuroprotective agents in the therapy of neuronal disorders of the central and peripheral nervous systems
03/31/2005US20050069276 Deuterated pyrazolopyrimidinones and drugs containing said compounds
03/31/2005DE10338554A1 Pentafluorosulfanylphenyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament Pentafluorosulfanylphenyl-substituted benzoylguanidines, processes for their preparation, their use as a medicament or diagnostic, and they drug-containing
03/31/2005DE10331202A1 Verwendung von Molkenpermeat zur Behandlung des Metabolischen Syndroms Use of whey permeate for the treatment of metabolic syndrome
03/31/2005CA2551037A1 Novel piperidine derivative
03/31/2005CA2539554A1 Phenylacetic acid derivative, process for producing the same, and use
03/31/2005CA2539288A1 Thyroid hormone analogs and methods of use
03/31/2005CA2539276A1 Methods of preventing or treating recurrence of myocardial infarction
03/31/2005CA2539230A1 Combinations of a vegf receptor inhibitor with other therapeutic agents
03/31/2005CA2539229A1 Oral compositions comprising vitis vinifera, gingko biloba and centella asiatica for the treatment of cellulite
03/31/2005CA2539181A1 Modulation of eif4e expression
03/31/2005CA2539165A1 Cinnamoyl compound and use of the same
03/31/2005CA2539162A1 Cinnamoyl derivatives and use thereof
03/31/2005CA2539159A1 Aminoalkylamide substituted cyclohexyl derivatives
03/31/2005CA2538960A1 Cinnamoyl compound and use of the same
03/31/2005CA2538366A1 Concurrent drugs
03/31/2005CA2537094A1 Novel adenosine a3 receptor agonists
03/30/2005EP1518549A1 A pellet comprising a local anesthetic agent and a radiopaque material
03/30/2005EP1518517A2 Drug-delivery endovascular stent and method for treating restenosis
03/30/2005EP1517924A1 Process for the manufacture of n-acyl-(epi)k5-amine-o-sulfate-derivatives and products thus obtained
03/30/2005EP1517912A2 Methods and compositions to treat pain and painful disorders using 577, 20739 or 57145
03/30/2005EP1517909A2 Novel tetracyclic arylcarbonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them
03/30/2005EP1517908A2 Novel benzimidazole derivatives
03/30/2005EP1517905A1 Processes for preparing substituted pyrimidines and pyrimidine derivatives as inhibitors of protein kinases
03/30/2005EP1517897A2 Benzimidazole compounds and their use as estrogen agonists/antagonists
03/30/2005EP1517896A2 Phenyl- and pyridyl-diazaheterocycles having a tnf-modulating activity
03/30/2005EP1517892A1 Ring-substituted diphenyl azetidinones, method for the production thereof, medicaments containing said compounds, and use thereof
03/30/2005EP1517891A1 Diphenyl azetidinones substituted by acidic groups, method for their production, medicaments containing said compounds and use thereof
03/30/2005EP1517890A1 Cationically substituted diphenyl azetidinones, method for their production, medicaments containing said compounds and use thereof
03/30/2005EP1517889A2 Nitrooxyderivatives of cyclooxygenase-2 inhibitors
03/30/2005EP1517883A1 Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
03/30/2005EP1517882A1 Amide linker peroxisome proliferator activated receptor modulators
03/30/2005EP1517705A1 Dichloroacetate in combination with cardioprotective or hemodynamic drugs
03/30/2005EP1517685A1 2-(phenyl)-2h-pyrazole-3-carboxylic acid-n-4-(thioxo-heterocyclyl)-phenyl-amide derivatives and corresponding imino-heterocyclyl derivatives and relates compounds for use as inhibitors of the coagulation factors xa and/or viia for treating thromboses
03/30/2005EP1517682A1 Pharmaceutical formulation comprising non-peptide renin inhibitor and surfactant
03/30/2005EP1517679A1 Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
03/30/2005EP1517672A1 Compositions and methods for amelioration of human female sexual dysfunction
03/30/2005EP1517653A1 Methods and devices for treating aneurysms
03/30/2005EP1390025B1 Use of coenzyme q (ubiquinone) and eicosapentaenoic acid (epa) for the treatment of non-hodgkin's lymphoma and psychiatric or neurological disorders
03/30/2005EP1360184B1 Piperidine derivatives as neurokinin 1 antagonists
03/30/2005EP1250092B1 Method for preventing fluorescence quenching
03/30/2005EP1242089B1 Use of adatanserin for the treatment of acute neurodegenerative disorders
03/30/2005EP1237898B1 N?6 heterocyclic 8-modified adenosine derivatives
03/30/2005EP1235831B1 New oxabispidine compounds useful in the treatment of cardiac arrhythmias
1 ... 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 ... 1595